Payment overview · 2025
General Payments
$124.55
7 reported records · 3 companies
Healthcare provider profile · identity verified
Luis Garcia Rivera, M.D.
Allopathic & Osteopathic Physicians|General Practice · LAKELAND, FL · NPI 1164539870
Verified facts
What the public records show
CMS Open Payments records show Luis Garcia Rivera, M.D. received $124.55 in general payments during 2025 across 7 reported records.
AstraZeneca Pharmaceuticals LP accounted for 55.2% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 5 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 75 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Symbicort by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $68.78 | 55.2% | 4 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $34.31 | 27.6% | 2 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $21.46 | 17.2% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $124.55 | 7 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $49.78 | 3 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $34.31 | 2 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $21.46 | 1 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $19.00 | 1 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $17.01 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 75 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
75 | 21 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 479 | 242 |
| Losartan Potassium | Losartan Potassium | 333 | 164 |
| Metformin Hcl | Metformin Hcl | 268 | 134 |
| Lisinopril | Lisinopril | 249 | 125 |
| Amlodipine Besylate | Amlodipine Besylate | 246 | 135 |
| Levothyroxine Sodium | Levothyroxine Sodium | 242 | 119 |
| Famotidine | Famotidine | 202 | 112 |
| Gabapentin | Gabapentin | 189 | 98 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 184 | 67 |
| Hydrochlorothiazide | Hydrochlorothiazide | 174 | 85 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 168 | 88 |
| Furosemide | Furosemide | 138 | 70 |
| Simvastatin | Simvastatin | 130 | 66 |
| Alprazolam | Alprazolam | 121 | 53 |
| Montelukast Sodium | Montelukast Sodium | 120 | 65 |
| Tamsulosin Hcl | Tamsulosin Hcl | 114 | 56 |
| Metoprolol Tartrate | Metoprolol Tartrate | 111 | 55 |
| Azithromycin | Azithromycin | 105 | 92 |
| Pantoprazole Sodium | Pantoprazole Sodium | 104 | 61 |
| Trazodone Hcl | Trazodone Hcl | 97 | 49 |
| Metoprolol Succinate | Metoprolol Succinate | 94 | 47 |
| Meloxicam | Meloxicam | 91 | 54 |
| Jardiance | Empagliflozin | 88 | 29 |
| Citalopram Hbr | Citalopram Hydrobromide | 85 | 38 |
| Omeprazole | Omeprazole | 85 | 57 |
| Eliquis | Apixaban | 83 | 24 |
| Fluticasone Propionate | Fluticasone Propionate | 78 | 43 |
| Farxiga | Dapagliflozin Propanediol | 75 | 21 |
| Carvedilol | Carvedilol | 74 | 41 |
| Tramadol Hcl | Tramadol Hcl | 73 | 37 |
| Clopidogrel | Clopidogrel Bisulfate | 72 | 36 |
| Glimepiride | Glimepiride | 70 | 34 |
| Ezetimibe | Ezetimibe | 67 | 32 |
| Januvia | Sitagliptin Phosphate | 66 | 17 |
| Pravastatin Sodium | Pravastatin Sodium | 63 | 30 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 62 | 21 |
| Hydralazine Hcl | Hydralazine Hcl | 58 | 29 |
| Prednisone | Prednisone | 57 | 48 |
| Baclofen | Baclofen | 56 | 37 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 56 | 19 |
| Dicyclomine Hcl | Dicyclomine Hcl | 53 | 20 |
| Folic Acid | Folic Acid | 51 | 22 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 50 | 25 |
| Ibuprofen | Ibuprofen | 48 | 30 |
| Celecoxib | Celecoxib | 44 | 25 |
| Donepezil Hcl | Donepezil Hcl | 44 | 22 |
| Sildenafil Citrate | Sildenafil Citrate | 44 | 12 |
| Allopurinol | Allopurinol | 43 | 26 |
| Buspirone Hcl | Buspirone Hcl | 43 | 23 |
| Glipizide | Glipizide | 42 | 22 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 40 | 18 |
| Diclofenac Sodium | Diclofenac Sodium | 40 | 29 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 40 | 37 |
| Alendronate Sodium | Alendronate Sodium | 38 | 20 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 38 | 30 |
| Clonazepam | Clonazepam | 38 | 19 |
| Atenolol | Atenolol | 37 | 20 |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 37 | suppressed |
| Sucralfate | Sucralfate | 37 | 19 |
| Tizanidine Hcl | Tizanidine Hcl | 37 | 20 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 36 | 34 |
| Doxycycline Hyclate | Doxycycline Hyclate | 36 | 30 |
| Duloxetine Hcl | Duloxetine Hcl | 36 | 14 |
| Latanoprost | Latanoprost | 36 | 12 |
| Spironolactone | Spironolactone | 35 | 21 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 33 | 23 |
| Finasteride | Finasteride | 33 | 19 |
| Meclizine Hcl | Meclizine Hcl | 33 | 22 |
| Metformin Hcl Er | Metformin Hcl | 33 | 17 |
| Fenofibrate | Fenofibrate | 32 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 32 | 12 |
| Potassium Chloride | Potassium Chloride | 32 | 22 |
| Naproxen | Naproxen | 30 | 19 |
| Sertraline Hcl | Sertraline Hcl | 30 | 21 |
| Amitriptyline Hcl | Amitriptyline Hcl | 29 | 12 |
| Glipizide Er | Glipizide | 29 | 15 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 29 | 11 |
| Pregabalin | Pregabalin | 29 | 12 |
| Telmisartan | Telmisartan | 29 | 16 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 28 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 28 | 16 |
| Trulicity | Dulaglutide | 28 | 12 |
| Entresto | Sacubitril/Valsartan | 26 | suppressed |
| Gemfibrozil | Gemfibrozil | 26 | 11 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 26 | 13 |
| Zolpidem Tartrate | Zolpidem Tartrate | 26 | 12 |
| Enalapril Maleate | Enalapril Maleate | 25 | suppressed |
| Mupirocin | Mupirocin | 25 | 21 |
| Droplet Pen Needle | Pen Needle, Diabetic | 24 | suppressed |
| Novolin 70-30 | Insulin Nph Hum/Reg Insulin Hm | 24 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 24 | 12 |
| Fluoxetine Hcl | Fluoxetine Hcl | 23 | suppressed |
| Nifedipine Er | Nifedipine | 23 | 14 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 22 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 22 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 21 | 13 |
| Lorazepam | Lorazepam | 20 | suppressed |
| Memantine Hcl | Memantine Hcl | 20 | suppressed |
| Verapamil Er | Verapamil Hcl | 20 | 11 |
| Xarelto | Rivaroxaban | 20 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 19 | 14 |
| Fenofibrate | Fenofibrate,micronized | 19 | suppressed |
| Mirtazapine | Mirtazapine | 19 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 19 | suppressed |
| Ketoconazole | Ketoconazole | 18 | 11 |
| Novolog Flexpen | Insulin Aspart | 18 | suppressed |
| Promethazine-Dm | Promethazine/Dextromethorphan | 18 | 11 |
| Ropinirole Hcl | Ropinirole Hcl | 18 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 18 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 18 | suppressed |
| Alcohol Prep Pads | Alcohol Antiseptic Pads | 17 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 17 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 17 | suppressed |
| Nitroglycerin | Nitroglycerin | 17 | 11 |
| Ozempic | Semaglutide | 17 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 17 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 17 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 17 | suppressed |
| Ammonium Lactate | Ammonium Lactate | 16 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 16 | suppressed |
| Dexamethasone | Dexamethasone | 16 | 15 |
| Fluconazole | Fluconazole | 16 | 13 |
| Insulin Lispro | Insulin Lispro | 16 | suppressed |
| Ssd | Silver Sulfadiazine | 16 | 13 |
| Tradjenta | Linagliptin | 16 | suppressed |
| Cilostazol | Cilostazol | 15 | suppressed |
| Humulin 70-30 | Insulin Nph Hum/Reg Insulin Hm | 15 | suppressed |
| Lovastatin | Lovastatin | 15 | 11 |
| Novolog | Insulin Aspart | 15 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 15 | suppressed |
| Synthroid | Levothyroxine Sodium | 15 | suppressed |
| Comfort Ez Pen Needle | Pen Needle, Diabetic | 14 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 14 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 14 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 14 | suppressed |
| Amoxicillin | Amoxicillin | 13 | 13 |
| Levofloxacin | Levofloxacin | 13 | 12 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 13 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 13 | 12 |
| Stiolto Respimat | Tiotropium Br/Olodaterol Hcl | 13 | suppressed |
| Temazepam | Temazepam | 13 | suppressed |
| Cyanocobalamin Injection | Cyanocobalamin (Vitamin B-12) | 12 | suppressed |
| Diltiazem 24hr Er | Diltiazem Hcl | 12 | suppressed |
| Nabumetone | Nabumetone | 12 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 12 | suppressed |
| Ranolazine Er | Ranolazine | 12 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 12 | suppressed |
| Advair Hfa | Fluticasone Propion/Salmeterol | 11 | suppressed |
| Diazepam | Diazepam | 11 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 11 | suppressed |
| Humulin 70/30 Kwikpen | Insulin Nph Hum/Reg Insulin Hm | 11 | suppressed |
| Insulin Lispro Protamine Mix | Insulin Lispro Protamin/Lispro | 11 | suppressed |
| Methylprednisolone | Methylprednisolone | 11 | 11 |
| Olanzapine | Olanzapine | 11 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 11 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 11 | suppressed |
| Rabeprazole Sodium | Rabeprazole Sodium | 11 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 11 | suppressed |
| Vascepa | Icosapent Ethyl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $124.55 · 7 records | AstraZeneca Pharmaceuticals LP | AIRSUPRA, FARXIGA, FREESTYLE LIBRE 3, OTEZLA, REPATHA | 2 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error